Renal Nerve Ablation for Resistant Hypertension

Abstract

HomeCirculationVol. 129, No. 13Renal Nerve Ablation for Resistant Hypertension Free AccessResearch ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessResearch ArticlePDF/EPUBRenal Nerve Ablation for Resistant HypertensionHow Did We Get Here, Present Status, and Future Directions Vasilios Papademetriou, MD, Amir Adel Rashidi, MD, Costas Tsioufis, MD and Michael Doumas, MD Vasilios PapademetriouVasilios Papademetriou From the Department of Veterans Affairs and Georgetown University, Washington, DC (V.P., A.A.R.); Ippokration University Hospital, Athens, Greece (C.T.); Aristotle University of Thessaloniki, Thessaloniki, Greece (M.D.). Search for more papers by this author , Amir Adel RashidiAmir Adel Rashidi From the Department of Veterans Affairs and Georgetown University, Washington, DC (V.P., A.A.R.); Ippokration University Hospital, Athens, Greece (C.T.); Aristotle University of Thessaloniki, Thessaloniki, Greece (M.D.). Search for more papers by this author , Costas TsioufisCostas Tsioufis From the Department of Veterans Affairs and Georgetown University, Washington, DC (V.P., A.A.R.); Ippokration University Hospital, Athens, Greece (C.T.); Aristotle University of Thessaloniki, Thessaloniki, Greece (M.D.). Search for more papers by this author and Michael DoumasMichael Doumas From the Department of Veterans Affairs and Georgetown University, Washington, DC (V.P., A.A.R.); Ippokration University Hospital, Athens, Greece (C.T.); Aristotle University of Thessaloniki, Thessaloniki, Greece (M.D.). Search for more papers by this author Originally published1 Apr 2014https://doi.org/10.1161/CIRCULATIONAHA.113.005405Circulation. 2014;129:1440–1451IntroductionSympathetic renal denervation, or renal nerve ablation (RNA), has become the new buzz word in hypertension and interventional cardiology. Recent advances in catheter-based approaches have allowed sympathetic fiber interruption through transvascular techniques that are minimally invasive and can be delivered expeditiously and safely. Radiofrequency (RF) energy sources are currently the preferred modalities, but other sources of energy, such as cryoablation, microwave, high-intensity focus ultrasound, and local neurotoxic agent infusion, are under intense investigation. Results thus far have been encouraging and offer promise for the future. The role of the sympathetic nervous system (SNS) in the development of resistant hypertension and cardiovascular disease has long been known, and a great deal of work has been done through the years trying to explore potential interventions to interrupt the sympathetic influence on systemic vasculature and target organs. In this article we attempt an overview of time-dependent interventions on the SNS and examine approaches used in humans and in the many experimental models that offer a better understanding of the role of sympathetic activity in cardiovascular disease. Naturally we focus on methods and techniques addressing sympathetic renal denervation in patients with drug-resistant hypertension, examine the current state of the art, and attempt a look into the future.Historic PerspectiveIn 1889, after meticulous experiments on dogs, Bradford1 reported that stimulation of dorsal and splanchnic nerves causes changes in blood pressure (BP) and kidney size measured by plethysmography. Whether BP increased or decreased depended on the anatomic area stimulated, as well as the electric impulse frequency, but outcomes were consistent and reproducible. Neurosurgical treatment of hypertension was independently suggested by researchers in 1923.2 Adson, however, was the first to performed surgical sympathectomy for the treatment of malignant hypertension in 1925.3 During the following years and in the 1930s, Peet in Ann Arbor, Page and Heuer in New York, and Adson, Craig, and Brown from the Mayo Clinic operated and reported on series of patients all experiencing malignant hypertension.4 At the same time, renal decapsulation, which was considered a form of sympathectomy by disrupting the fibers between the capsule and the renal cortex, was being performed to treat unexplained hematuria and perinephritis. Sen5 reported a significant but not permanent decrease in BP in 85 subjects who underwent decapsulation between 1925 and 1935.Surgical denervation of the kidneys alone was first performed in humans by Papin and Ambard6 in 1924 in an attempt to relieve intractable pain originating from the kidney. The first case of bilateral sympathetic denervation of the kidney to treat severe essential hypertension was presented in 1934 by Page and Heuer.7 The patient was a 25-year–old woman who reported easy fatigability and had severe headaches and BP in the range of 208/140 mm Hg. The patient underwent surgical staged, bilateral renal sympathectomy with no clinically meaningful effect on BP after follow-up for 5 months. However, the case established that the procedure was safe and had no negative effect on renal function. In 1935, Page and Heuer8 reported bilateral renal denervation in 5 patients with chronic and progressive nephritis, which resulted in no change in renal clearance or concentrating ability of the kidney but caused diminished proteinuria and a decrease in BP that lasted for months in the majority of those patients. Because of these early unsatisfactory results, surgical renal denervation gave way to the more radical sympathectomy procedure, the surgical removal of splanchnic nerves (splanchnicectomy), which showed dramatic results in the majority of patients with malignant hypertension. Peet published series and case reports of patients with malignant hypertension responding in a dramatic way to supradiaphragmatic splanchnicectomy.9Figure 1 shows the BP response of a 22-year–old patient with known severe hypertension for >3 years. She had been in bedrest for 8 months because of the severity of symptoms, yet her BP remained at 280/190 mm Hg. Fundoscopic examination revealed stage IV retinopathy with evidence of early papilledema, flame-shaped hemorrhages, and cotton wool exudates. On June 24, 1934 she underwent bilateral supradiaphragmatic splanchnicectomy, and postoperatively her BP was reduced to 110/90 mm Hg. Fundoscopic examination 2 months later demonstrated complete resolution of papilledema, with hemorrhages and exudates resolved. The patient became asymptomatic, and 13 years later was free of any hypertensive complications with BP, remaining within the normal range (Figure 1).Download figureDownload PowerPointFigure 1. Blood pressure response to splanchnicectomy in a young woman with malignant hypertension: a 13-year postoperative follow up. Reprinted from Peet9 with permission from the American Journal of Surgery.Since then and for the subsequent 2 decades, surgical sympathectomy (thoracolumbar splanchnicectomy) became the procedure of choice for patients with severe/malignant hypertension not responding to diet or to then-limited pharmacologic therapy. Between 1938 and 1947, Smithwick and Thompson10 published results from 3500 patients with severe/malignant hypertension. Of those, 2400 patients underwent thoracolumbar splanchnicectomy, and the rest were followed on a medical regimen. Of those, 1266 patients who had splanchnicectomy, and 467 patients on medical therapy had follow-up of 5 to 14 years and were included in the final analysis. At 5 years of follow-up, all-cause mortality was 19% in the surgical series and 54% in the medically treated patients. Of the surgically treated patients, only 45% demonstrated substantial BP reduction, but mortality benefits were realized across the board. Peet et al11 reported 51.4% significant BP reduction and 3.4% operative mortality in 350 patients with severe/malignant hypertension. However, an important limiting complication was postural hypotension, which was encountered in many patients postoperatively.In the mid-1950s the first oral antihypertensive medication became available for the treatment of hypertension, and for the first time a well-tolerated regimen could be given long term.12 Pharmacologic therapy helped treat many patients with severe hypertension, and the number of patients progressing to accelerated/malignant stage gradually diminished,13 thus settling the issue for the next 5 decades. Very few patients not responding to pharmacologic therapy have been referred for splanchnicectomy in recent years. However, during this time a great deal of research has been pursued to uncover and better understand the role of the SNS and, in particular, of the renal sympathetic nerves in the development and maintenance of hypertension.14A wealth of experimental data in animals and humans point toward an important role of SNS overactivity for the development and persistence of hypertension.15 Excessive SNS activity is involved in the metabolic syndrome, obesity, structural and functional myocardial alterations,16 and several other disease states, including congestive heart failure (HF), chronic kidney disease, polycystic ovary syndrome, obstructive sleep apnea, and cirrhosis.17–21 SNS regulation is multifactorial, and several mechanisms modulate sympathetic activity.15Renal Nerves: Efferent and Afferent Sympathetic FibersKidneys act both as generators and recipients of sympathetic signals (Figure 2).22 Sympathetic afferent fibers originate from the kidneys and travel to the central nervous system, where, after processing, coordinated by the nucleus tractus solitaries of the midbrain, they regulate sympathetic outflow and promote SNS overactivity in response to renal injury.23 On the other hand, renal efferent sympathetic nerves originate from the brain, travel through the spinal cord, reach the kidney from the second sympathetic ganglia, course through the adventitia of the renal arteries, and innervate the peripheral segments in the renal cortex, ending in glomerular arterioles, where they can affect renal function. Overactivity of the efferent sympathetic fibers results in enhanced renin release, increased sodium and water absorption, reduced renal blood flow, and glomerular filtration rate.24 It seems that both the afferent and efferent fibers contribute to the development and persistence of hypertension.Download figureDownload PowerPointFigure 2. Diagram depicting the influence of efferent and afferent sympathetic fibers in modulating sympathetic responses of the kidney, the heart, the vasculature, and other target organs.By the 1980s it was well established that kidneys are important sensory organs with abundant baroreceptors and chemoreceptors and significant afferent innervation. In 1987, Webb and Brody25 published results from a thesis in which they addressed signal trafficking via the afferent sympathetic fibers in a rat model. Through extensive instrumentation and careful monitoring, they demonstrated that electric stimulation of afferent sympathetic fibers can reduce BP in a dose-dependent manner. They also demonstrated that BP responses could be abolished by spinal transection and interruption of the efferent sympathetic fibers coursing through the spine. Subsequently, in a controlled study, Campese and Kogosov26 showed that resection of the afferent renal nerves through ventral rhizotomy can prevent activation of the noradrenergic neurons in the hypothalamus and can prevent the development of hypertension in rats with chronic renal insufficiency.In other studies, Converse et al27 showed that patients on hemodialysis who have undergone bilateral nephrectomy have significantly lower peripheral vascular resistance and BP. Similar findings were reported by Hausberg et al28 in renal transplant recipients before and after surgical removal of native kidneys. Bilateral nephrectomy results in the interruption of both the afferent and efferent sympathetic fibers.Renal nerve stimulation results in vasoconstriction of the renal vasculature.29 Others have demonstrated that sympathetic nerve endings directly release norepinephrine on renal epithelial cells and can cause a 30% to 40% increase in sodium and water reabsorption via α–1 adrenergic receptors even before any hemodynamic changes could be detected.30,31 In 1981, Osborn et al32 demonstrated that low-frequency stimulation of the renal nerve in dogs can directly mediate renin secretion via β-1 adrenergic receptors. In other experiments, surgical renal denervation has been shown to affect hypertension. In deoxycorticosterone acetate–treated miniature swine with established hypertension, O’Hagan et al33 demonstrated that renal denervation results in immense natriuresis and BP reduction. Similarly, Huang et al34 in a hyperinsulinemia-induced hypertension model demonstrated that renal denervation can prevent hypertension development if done early or can normalize BP after hypertension is established (Figure 3).Download figureDownload PowerPointFigure 3. Renal denervation in 2 animal models. A, Immense natriuresis and blood pressure reduction in a deoxycorticosterone acetate (DOCA)-treated miniature swine model. B, Prevention of hypertension with early renal nerve ablation (RNA) and blood pressure (BP) reduction to normal when RNA was performed 4 weeks after insulin infusion. Reprinted from Huang et al34 with permission from Hypertension and from O’Hagan et al33 with permission from American Journal of Hypertension.RNA for Drug-Resistant HypertensionRenal sympathetic denervation has been performed, through the years, both in experimental models and in humans by surgical exposure of renal nerves. The renal nerves were interrupted or resected using mostly a surgical scalpel, although later electrocautery, cryoablation, and thermal (RF) ablation have also been used. With progress in technology and the advent of transcatheter techniques, it was natural to progress to transvascular methods to interrupt nerve integrity. Catheter-based RF ablation techniques have been used in electrophysiology for more than 2 decades to ablate accessory pathways and abnormal cardiac structures in patients with Wolff-Parkinson-White syndrome or supraventricular and ventricular arrhythmia. In 1999, a series of experiments completed at the University of Oklahoma using a basket catheter demonstrated that it was possible to stimulate and ablate autonomic nerves on the outside of blood vessels. Notably, Schauerte et al used an innovative approach to stimulate35 and ablate36 the vagal nerve to treat patients with vagally mediated atrial fibrillation (AF). RF energy was applied transvascularly to ablate the vagal nerve. The currently used technique for catheter-based RNA uses a very similar concept.Patients with drug-resistant hypertension have increased sympathetic outflow. Resistant hypertension is defined as failure to achieve BP goals despite the use of at least 3 antihypertensive drugs, 1 of which is a diuretic. The exact prevalence of resistant hypertension is not known, but by current estimates, ≈12% of patients with hypertension are resistant to treatment.37,38 This would translate into ≈120 million patients worldwide.Given resistance to drug therapy, activation of SNS, the role of renal nerves in the development of hypertension, and the ease of approach of the sympathetic fibers by catheter based techniques, resistant hypertension was the perfect candidate for interventional approaches.39 Sympathetic fibers course in the adventitia of the renal arteries, are mostly situated within 2 to 3 mm from the inner layer of the renal artery,40 and can be easily reached and interrupted transvascularly using thermal energy. To date, RF thermal energy has been delivered using either a single-tip electrode catheter or multielectrode systems. The objective of RF ablation is to place discrete lesions in a circumferential pattern but not at the same cross-section of the vessel, so as to minimize the risk of renal artery stenosis.As of today, 6 devices received the CE marking to be used for RNA. The first device used in humans (Symplicity/Ardian, Metronic) was a 6-French, steerable RF ablation catheter inserted percutaneously through a femoral sheath and a guide catheter engaging each renal artery sequentially.41 This catheter is easy to use but it creates lesions with a less predictable geometric pattern. The St Jude’s multielectrode ablation system (EnligHTN) has 4 electrodes mounted on a basket that can easily achieve circumferential distribution of lesions. The basket is collapsed, can be expanded by an external mechanism, can achieve good wall apposition, and can deliver thermal injury and fiber interruption in a desirable and predictable way. The other 2 systems, the Vessix V2 system (Vessix Vascular-Boston Scientific), and the OneShot system (Covidien), have the electrodes mounted on a balloon. The Iberis system (Terumo) has a 4-French shaft that enables radial access. The Paradise system using ultrasound technology has also been approved in Europe (ReCor Medical). Below we briefly review the studies performed to date and attempt a well-intended critique of existing data.The first in-human proof-of-concept study (Symplicity I) evaluated 50 patients with treatment-resistant hypertension.41 Of those, 45 were eligible for RNA and composed the treatment group. BP reduction with RNA was significant, smaller in the first month after RNA (–14/–10 mm Hg), and more pronounced at 6-month and 1-year follow-up (–27/–17 mm Hg; Figure 4). Ambulatory BP monitoring (ABPM) was done in a small number of patients and demonstrated much less BP reduction (–11 mm Hg for systolic BP [SBP]).Download figureDownload PowerPointFigure 4. Baseline office and 24-hour ambulatory blood pressures and changes after renal denervation in 5 studies that included both office and ambulatory blood pressure measurements (ABPM).The second study was randomized but not blinded and performed soon after in a larger sample of 106 patients with resistant hypertension and similar characteristics to the proof-of-concept study.42 RNA was performed in 52 patients, whereas standard antihypertensive medications were continued in the remaining 54 patients. BP dropped significantly in the first month in the active RNA group, but BP reduction was much greater at 6 months (–32/–12 mm Hg). BP change was minimal in the control group (1/0 mm Hg). BP reduction was significantly less in a smaller group of 20 patients who underwent ambulatory BP measurement (–11/–7 mm Hg).The Symplicity trials created a great deal of enthusiasm and captured the imagination of the hypertension and interventional community alike. Nevertheless, these early studies were accompanied by a number of questions and inconsistencies, described below.Initial office BP reduction was modest and improved with time. The number of patients reported at each time point was different (smaller at later time points), which raises the possibility that nonresponders were excluded. Other possibilities include regression to the mean, improvement in patient compliance, medication manipulation, or lifestyle changes. Remodeling of resistance vessels has also been suggested by the authors. The lack of placebo effect noted in Symplicity II is also highly unusual for hypertension studies. The bigger problem, however, with the Symplicity and other trials is the discrepancy between office BP measurements and ABPM. A small disparity in office and average 24-hour ambulatory BP reduction is expected and has been reported previously; large disparities, however, are unusual and raise questions.43There was a considerable discrepancy between average office BP and average 24-hour BP at baseline, as well as a big difference in the magnitude of BP reduction during follow up in the Symplicity trials (Figure 4). Ambulatory BP was performed only in a small subset of patients (12 of 45 patients in Symplicity I and 20 of 49 patients in the active group of Symplicity II), and BP reduction was only 41% and 34% of office BP reduction in the 2 studies. A meta-analysis of antihypertensive drug therapy revealed that ambulatory BP reduction should be ≥65% of the reduction seen in office BP.44 Similar disparities have been noted in most recently published denervation trials.We recently reported the 6-month data from the first-in-human trial, EnligHTN I.45 This study included 46 patients with resistant hypertension and baseline characteristics similar to the Symplicity population. All of the patients underwent RNA using a standardized technique aiming to achieve complete renal denervation. In this first in-human study, office BP was reduced significantly and substantially in the first month (–28/–10 mm Hg) and remained at the same levels for ≤6 months. Results from all of the patients were reported at all of the time points. Ambulatory BP measurement was performed in all of the patients and demonstrated a ≤10/≤5-mm Hg reduction in average 24-hour BP, which also remained the same until the 6-month follow-up. However, the discrepancy between office and ambulatory BP reduction remained. Baseline office SBP and heart rate correlated significantly with BP response at 6 months.46Although several other studies reported significant BP reduction after RNA, only a few performed ABPM to evaluate the magnitude of BP reduction (Figure 4). A small study was performed by Witkowski et al47 in 10 patients with sleep apnea and drug-resistant hypertension. The authors found a significant reduction in office BP at 3 and 6 months after RDN (–34/–13 mm Hg) but only a small change in SBP measured by ABPM (–6 mm Hg). Another small study, by Hering et al,48 in 15 patients with moderate and severe chronic kidney disease and resistant hypertension showed impressive office BP reduction at 3 and 6 months post-RNA (–27/–14 and –29/–14 mm Hg, respectively), but ABPM reductions were small and did not reach statistical significance (–6/–7 and –5/–6 mm Hg, respectively). A pilot study using the OneShot system in 8 patients with resistant hypertension showed similar results.49 After RNA, office BP was reduced by –34/–12 mm Hg at 6 months, but ABPM reductions were once again disappointingly small (–3/–4 mm Hg).Recently, a larger study presented a series of patients who underwent RNA for resistant hypertension and specifically examined the BP response as measured by ABPM.50 In this study, 346 patients with uncontrolled hypertension were evaluated. Of those, 303 patients were found by daytime ABPM to have true resistant hypertension, and 43 had pseudoresistant hypertension (office SBP, 161±20 mm Hg; 24-hour SBP, 121±20 mm Hg). At 3, 6, and 12 months of follow-up, office SBP was reduced by 21/24/27 mm Hg and office diastolic BP by 9/9/12 mm Hg. In patients with true treatment-resistant hypertension, there was a significant reduction in 24-hour SBP (10/10/12 mm Hg; P<0.001) and diastolic BP (5/5/7 mm Hg; P<0.001) at 3, 6, and 12 months, respectively. There was no effect on ABPM in pseudoresistant patients, whereas office BP was reduced to a similar extent. The findings of this larger study were in line with the findings of the 2 Symplicity trials and the EnligHΤΝ I study, confirming the antihypertensive effect of RNA but once again demonstrating a much smaller BP reduction when assessed by ABPM. This article was accompanied by an editorial that criticized the results.51Figure 4 presents baseline office and 24-hour ambulatory BPs and BP changes after RNA in 5 studies that included both measures. Consistently the ABPM measurements are substantially lower than the office measurements.The mechanisms underlying the disparity between office and ambulatory BP reduction remain poorly understood. We proposed recently that the white coat effect might be implicated, at least in part,43 whereas regression to the mean and other unclarified mechanisms might also apply. Of great interest, the reduction in office and ambulatory BP was almost identical in a recent study of 54 patients with moderate true resistant hypertension (office BP between 140/90 and 160/100 mm Hg).52 The findings of the latter study offer another potential contributing factor, that is, the level of BP values before applying RNA. It is known that the magnitude of BP reduction greatly depends on pretreatment levels, both with drug therapy53 and RNA.54,55 It is therefore expected for BP reduction to be larger when pretreatment BP is higher (usually the office BP) than when it is lower (usually the ambulatory BP). Indeed, it was found that the reduction in ambulatory BP tends to approach the office BP fall as the pretreatment BP levels become lower.56 However, further basic and clinical research is needed to clarify the mechanisms underlying the disparity and identify ways to overcome this problem.Other published studies presented negative results. In 1 study, 12 patients with difficult-to-control hypertension underwent RNA,57 and results were recorded before and 5 months after denervation. Results indicated that RNA did not change resting muscle sympathetic nerve activity, heart rate, or heart rate variability, and there was no change in office BP. One explanation for the results of this study is patient selection. Patients had lower baseline BP (157/85 mm Hg), and more importantly many of them (5 of 12; 42%) had normal BP (SBP <140 mm Hg), questioning the choice of RNA for patient management.58 Furthermore, there was no evidence of sympathetic activation (heart rate of 60 beats per minute and normal muscle sympathetic nerve activity discharge) at baseline;59 despite this, heart rate was reduced in 60% of these patients.Future Directions: Other Potential Applications of RNARNA might be beneficial in other disease states characterized by enhanced sympathetic activity, including chronic kidney disease, congestive HF, sympathetically driven arrhythmias, obstructive sleep apnea, and polycystic ovary syndrome. RNA may eventually find a role as a supplemental procedure to improve outcomes in high-risk patients, such as patients with coronary heart disease and or chronic kidney disease. The Table presents a number of disease states accompanied by sympathetic overactivity that potentially can benefit from RNA. Case reports or small pilot studies have been reported in many of these populations and they are briefly mentioned below.Table. Potential Targets for Renal Denervation Across the Cardiometabolic Continuum and Other Disease States Associated With Enhanced Sympathetic ActivityCardiometabolic TargetsOther Disease StatesMetabolic syndrome*Chronic kidney disease 1-3a‡Obesity*Chronic kidney disease 3b-4†Diabetes mellitus†Chronic kidney disease ESRD†Hypertension mild*Chronic kidney disease peritonealHypertension difficult to control†hemodialysis*Hypertension resistant‡Polycystic kidney disease†Atherosclerosis*Loin hematuria*Coronary artery disease*Obstructive sleep apnea†Left ventricular hypertrophy†Polycystic ovary syndrome†Diastolic LV dysfunction†Cirrhosis*Heart failure with preserved EF*Systolic heart failure†Atrial fibrillation†Ventricular tachyarrhythmia†Sudden death*LV indicates left ventricular; EF, ejection fraction; ESRD, end-stage renal disease.*No data available.†Limited data available.‡Robust data available.HypertensionDrug-resistant hypertension will remain the primary target for RNA, because this is a population with unmet medical need and data so far look encouraging. When the randomized, blinded control trials in the United States are completed (assuming positive results), RNA may become the procedure of choice for these patients. Before getting there, however, attention should be focused on key issues, such as preprocedural diagnostic workup, eligibility criteria for RNA, predictors of response, and markers of success.The diagnostic workup should aim to exclude secondary causes of resistance (renal artery stenosis, primary hyperaldosteronism, pheochromocytoma, hyperthyroidism, etc), anatomic abnormalities that would preclude RNA (multiple, small caliper renal arteries or very tortuous or heavily calcified renal arteries), and most importantly white coat hypertension. Large observational studies have shown that white coat hypertension can be detected in approximately one third of patients with resistant hypertension.38 The importance of pseudoresistance has been highlighted in the study by Mahfoud et al,50 which demonstrated no response to RNA measured by ABPM in this population. We, therefore, strongly believe that ABPM should be mandatory in all patients considered for RNA to exclude pseudoresistance.43 Adherence to drug therapy and lifestyle modification should also be thoroughly assessed, because they frequently account for drug resistance. Furthermore, optimization of the drug regimen to include an aldosterone antagonist (spironolactone or eplerenone) should be implemented in most patients before considering RNA. Exceptions, however, can be considered for patients with drug-resistant hypertension because of habitual noncompliance or inability or unwillingness to take prescribed medication.The criteria for RNA eligibility currently include patients with resistant hypertension and SBP levels >160 mm Hg (150 mm Hg for patients with diabetes mellitus and established cardiovascular disease), largely on the basis of the 2 Symplicity trials and the EnligHTN I study. However, pilot studies already explore the efficacy and safety of RNA in milder forms of resistant hypertension, that is, SBP between 140 and 160 mm Hg. In 2 studies of 20 and 54 such patients, BP was reduced by 13/5 and 13/7 mm Hg, respectively, at 6 months post-RNA.52,60 The European Society of Hypertension and the European Society of Cardiology have recently published position articles regarding RNA in an effort to clarify eligibility criteria and avoid the wide application of RNA in patients with questionable efficacy.61,62Efforts to identify predictors of response and